Adverse events to antiretrovirals in the Swiss HIV Cohort Study: Effect on mortality and treatment modification

Antiviral Therapy

Volumn 12, Issue 8, 2007, Pages 1157-1164

  Keiser, Olivia ^a   Fellay, Jacques ^b   Opravil, Milos ^c   Hirsch, Hans H ^d   Hirschel, Bernard ^e   Bernasconi, Enos ^f   Vernazza, Pietro L ^g   Rickenbach, Martin ^h   Telenti, Amalio ^b   Furrer, Hansjakob ⁱ   Battegay, M ^l   Bernasconi, E ^l   Boni J ^l   Bucher, H ^l   Burgisser Ph ^l   Cattacin, S ^l   Cavassini, M ^l   Dubs, R ^l   Egger, M ^l   Elzi, L ^l   Erb, P ^l   Fischer, M ^l   Flepp, M ^l   Fontana, A ^l   Francioli, P ^b   Furrer, H ^j   Gorgievski, M ^l   Gunthard H ^l   Hirschel, B ^l   Hosli I ^l   Kahlert, Ch ^l   Kaiser, L ^l   Karrer, U ^l   Keiser, O ^l   Kind, C ^l   Klimkait, Th ^l   Ledergerber, B ^l   Martinez, B ^l   Muller N ^l   Nadal, D ^l   Opravil, M ^l   Paccaud, F ^l   Pantaleo, G ^l   Perrin, L ^l   Piffaretti, J C ^l   Rickenbach, M ^k   Rudin, C ^l   Schmid, P ^l   Schultze, D ^l   Schupbach J ^l   Speck, R ^l   Taffe P ^l   Tarr, P ^l   Telenti, A ^l   Trkola, A ^l   Vernazza, P ^l   Weber, R ^l   Yerly, S ^l   more..

^a UNIVERSITY OF BERN   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h Swiss HIV Cohort Study Data Center   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j Clinical and Laboratory Committee

^k Data Centre

^l Department of Mother and Child Substudy ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL DISEASE; ADULT; ANEMIA; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIVARIATE ANALYSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SCORING SYSTEM; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; SWITZERLAND; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 38049075246     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322-1327.
2. Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis 2000; 13:5-11.
3. Powderly WG. Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 2002; 29 Suppl 1:S28-S40
4. Herman JS, Easterbrook PJ. The metabolic toxicities of antiretroviral therapy. Int J STD AIDS 2001; 12:555-562.
5. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
6. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14:F25-F32.
7. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004; 170:229-238.
8. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 2003; 34:379-386.
9. Sudre P, Rickenbach M, Taffé P, et al. Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000. Schweiz Med Wochenschr 2000; 130:1493-1500.
10. Lundgren JD, Mocroft A. Anaemia and survival in human immunodeficiency virus. Clin Infect Dis 2003; 37 Suppl 4:S297-S303.
11. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002; 31:50-55.
12. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2003; 2:624-634.
13. Silverberg MJ, Gore ME, French AL, et al. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the women's interagency HIV study. Clin Infect Dis 2004; 39:717-724.
14. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-265.
15. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
16. Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-686.
17. van Sighem AI, van de Wiel MA, Ghani AC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003; 17:2227-2236.
18. Moreno A, Perez-Elias MJ, Casado JL, et al. Effectiveness and pitfalls of initial highly active antiretroviral therapy in HIV-infected patients in routine clinical practice. Antivir Ther 2000; 5:243-248.
19. Mocroft A, Kirk O, Barton SE, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999; 13:943-950.
20. Moore RD, Keruly JC, Chaisson RE. Anaemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retroviral 1998; 19:29-33.
21. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
22. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev 2003; 5:36-43.
23. Kottilil S, Polis MA, Kovacs JA. HIV infection, hepatitis C infection, and HAART: hard clinical choices. JAMA 2004; 292:243-250.
24. Jain MK, Skiest DJ, Cloud JW, Jain CL, Burns D, Berggren RE. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003; 36:1030-1038.
25. Thio CL, Seaberg EC, Skolasky R, Jr., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
26. Mocroft A, Soriano V, Rockstroh J, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19:2117-2125.
27. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
28. Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health 2004; 94:1133-1140.
29. Carr A. Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy. Lancet 2002; 360:81-85.